NF2

Clinical trials for NF2 explained in plain language.

Never miss a new study

Get alerted when new NF2 trials appear

Sign up with your email to follow new studies for NF2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill aims to shrink tumors in rare nerve disorder

Disease control Not yet recruiting

This early-phase trial tests an oral drug called Trineumin (PRG-N-01) in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors on nerves. The study has two parts: first finding a safe dose, then checking if that dose can shrink tumor…

Matched conditions: NF2

Phase: PHASE1, PHASE2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:13 UTC

NF2

Get alerted when new NF2 trials appear

New pill aims to shrink tumors in rare nerve disorder